Related Experiment Videos
Prostatic neuroendocrine tumor in multiple endocrine neoplasia Type 2B
B Goulet-Salmon1, E Berthe, S Franc
1Department of Endocrinology Hospital CHU, Caen, France. bsalmon@ch-aleucom.fr
Journal of Endocrinological Investigation
|February 19, 2005
Summary
Neuroendocrine prostate tumors are rare, especially in young males with Multiple Endocrine Neoplasia (MEN) 2B. Investigating MEN 2B markers in prostate tumors and prostate exams in MEN 2B patients can aid diagnosis and screening.
Area of Science:
- Oncology
- Endocrinology
- Urology
Background:
- Multiple Endocrine Neoplasia (MEN) 2B is a rare genetic disorder associated with increased risk of certain tumors.
- Neuroendocrine prostate tumors (NEPT) are an uncommon malignancy with distinct clinical and pathological features.
Observation:
- This study details the unusual presentation of NEPT in two young males diagnosed with MEN 2B.
- The patients exhibited characteristics aligning with MEN 2B, prompting further investigation into the tumor's origin.
Findings:
- Immunohistochemistry of tumor markers is crucial for distinguishing primary NEPT from metastatic medullary thyroid carcinoma (MTC) in MEN 2B patients.
- Specific MEN 2B hallmarks, such as elevated plasma thyrocalcitonin and urinary metanephrines, were considered in the differential diagnosis.
Implications:
- Systematic investigation of MEN 2B markers is recommended for patients with neuroendocrine prostate tumors.
- Routine prostate examinations should be considered in the periodic screening of male patients with MEN 2B to detect potential NEPT early.